抗体药物偶联物开创乳腺癌治疗新格局  

Landscape of antibody-drugconjugates for breast cancer treatment

作　　者：齐晓伟 叶松青[2] Qi Xiaowei;Ye Songqing(Department of Breast and Thyroid Surgery,First Affiliated Hospital of Army Medical University,Chongqing 400038,China;Department of Oncology,Fujian Provincial Hospital,Fuzhou 350001,China)

机构地区：[1]陆军军医大学第一附属医院乳腺甲状腺外科,重庆400038 [2]福建省立医院肿瘤外科,福州350001

出　　处：《中华乳腺病杂志（电子版）》2023年第3期129-135,共7页Chinese Journal of Breast Disease(Electronic Edition)

摘　　要：近年来,抗体药物偶联物(ADC)发展迅速,备受关注。作为一种有效的肿瘤靶向治疗药物,ADC兼具化疗药物强大的杀伤力与单克隆抗体药物高度的靶向性,疗效更好,不良反应更小。在乳腺癌领域,目前已有3种ADC获批国内上市,逐步改变乳腺癌治疗的格局。本文从ADC的研发历程、应用现状与未来展望3个方面进行总结,以期为ADC在乳腺癌中的临床应用及研究提供新思路。In recent years,antibody-drug conjugate(ADC)has developed rapidly and attracted much attention.As an effective drug for targeted therapy of tumors,ADC has both the powerful lethality of chemotherapy and the high targeting ability of monoclonal antibody drugs,showing better efficacy and fewer side effects.In the field of breast cancer,three ADC products have been approved for marketing in China,which are gradually changing the landscape of breast cancer treatment.This article summarizes the development process of ADC,the therapeutic pattern reshaping of breast cancer,and future prospect of ADC application,so as to provide new insights for clinical application and research of ADC.

关 键 词：乳腺肿瘤 人表皮生长因子受体-2 抗抗体药物偶联物 

分 类 号：R737.9[医药卫生—肿瘤]